Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Neuroblastoma 8Ganglioneuroblastoma 4Triple Negative Breast Neoplasms 3Melanoma 3Lung Neoplasms 3Carcinoma, Non-Small-Cell Lung 2Adenoma, Islet Cell 2Uterine Cervical Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Resectable Esophageal Cancer 1Neoplasms 1Neoplasm Metastasis 1Multiple Myeloma 1Locally Advanced Pancreatic Adenocarcinoma 1Leukemia, Plasma Cell 1Gliosarcoma 1Glioblastoma 1Endometrial Neoplasms 1Carcinosarcoma 1Carcinoma, Transitional Cell 1Carcinoma, Renal Cell 1Carcinoma, Merkel Cell 1Carcinoma, Intraductal, Noninfiltrating 1Carcinoma, Hepatocellular 1

Interventions

Granulocyte-Macrophage Colony-Stimulating Factor 1Colony-Stimulating Factors 1Chemoradiotherapy 1Adjuvants, Immunologic 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Resectable Esophageal Cancer × Colony-Stimulating Factors × 1 year × Clear all
NCT05307835 2025-12-02

Neoantigen Vaccine in Esophagus Cancer Patients Following Neoadjuvant Therapy and Surgical Resection

Second Affiliated Hospital, School of Medicine, Zhejiang University

Phase 1 Active not recruiting
27 enrolled
Gastrointestinal

Resectable Esophageal Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡